Patient-level concentration-time profiles of riliprubart mean plasma concentrations over the study period (15 weeks). 90% inhibitory concentration for CH50 is 57.0 μg/mL; this value correlates to inhibition of the CP that may provide therapeutic effect to patients with CAD. With the exception of 1 patient in the 30 mg/kg cohort who had low riliprubart exposure from the first timepoint, patients with CAD had similar concentration-time profiles to those of healthy participants. CH50, 50% hemolytic complement.